Baker Hughes Co vs Smith & Nephew plc — how do they compare? Baker Hughes Co trades at $57.78 (market cap $57.32B), while Smith & Nephew plc trades at $30.06 (market cap $12.40B). The key difference: Baker Hughes Co is far larger — about 4.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.62%). Which is the better fit depends on your goals.
| BKR | SNN | |
|---|---|---|
Market Cap | $57.32B | $12.40B |
Sector | Energy | Health |
52-Week High | $69.67 | $38.70 |
52-Week Low | $38.68 | $28.73 |
Enterprise Value | $58.72B | $15.17B |
Dividend Yield | 1.59% | 2.62% |
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $57.66, up 0.17% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a 66.7% buy rating from analysts, alongside a $74.09 price target, highlight positive momentum. The company secured key LNG and power infrastructure contracts, supporting growth in energy transition markets. Operating cash flow remains robust at $3.81B for 2025, though net income dipped slightly to $2.59B.
Outlook is positive driven by LNG expansion and AI-powered energy demand, but risks include oil price volatility and integration challenges from the Chart Industries acquisition. Valuation metrics like a P/E of 18.42 and ROE of 17.14% suggest reasonable pricing for growth prospects, though execution on new contracts is critical for sustained upside.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →